Baeza CJA, García AME, García AP

Language: Spanish
References: 3
Page: 30-34
PDF size: 96.10 Kb.

ABSTRACT

The bronchial reactivity can be defined as the obstruct answer of the air tract before pharmacological stimulus, like histamine and methacholine, that cause contraction of the smooth muscle of the air mail. The increase of the bronchial reactivity is one of the most characteristic alterations in the pathogenesis of the bronchial asthma, usually all the symptomatic asthmatic present it. Nevertheless it is necessary to keep in mind that this inconvenience is not specific, since a bronchial hyper-reactivity of smaller magnitude can be observed in normal individuals during the viral respiratory infections and in different illnesses as, allergic rhinitis, pulmonary tuberculosis and other. The allergic rhinitis is a risk factor to present bronchial hyper-reactivity (HPB), and to the inverse one, the HPB often is found in patients with rhinitis (17-25% in children and 20-50% in adults). More than the 80% of patients with HPB that in subsequent form they developed asthma they have rhinitis allergic, not allergic or both. The bronchial asthma has suffered an increment everywhere is estimated in a 10 to a 40% reported in the last World Congress of Allergy and Immunology organized by the IAAACI and the recent one WAO (World Organization of Allergy). The children less than 5 years are the most affected, for which is the pediatrician and/or the general practitioner who should know the factors of risk to indicate measures of prevention in the morbidity, severity and mortality of the asthma The recovery of the asthma on a worldwide basis, particularly with symptomatology in the pediatric age, stimulates al medicines associations study that can be complementary according to the illness physiopathology. Objective: The objective was to evaluate the efficacy and security of the oral administration of the combination ambroxol/ salbutamol/ loratadine in children from 2 to 6 years of age with bronchial hyper-reactivity induced by allergens. Material and methods: A clinical study was made in order to evaluate the efficacy, security, of the combination Salbutamol/ Ambroxol/ Loratadina, in patients in pediatric age from 2 to 6 years of age with diagnostic of bronchial hyper-reactivity. An initial clinical evaluation was performed that take in account the following symptoms and signs: Sibilants, productive cough, rhinitis. The intensity of each one of the symptoms and signs qualify themselves based on an ordinal scale in which the values were: Absent = 0, light = 1, moderate = 2, severe = 3. The intensity of the cough value itself also in four degrees: Absence = 0, low frequency = 1, constant = 2, frequent = 3. Only those that reached a score of 6 or greater they were included in the study. The patients selected received during a period from 10 days the combination salbutamol-ambroxol-loratadina orally and they were evaluated in the days 5 and 10 through a clinical study based on a system of score. Results: Differences among the values obtained in the pulse oximetry of 88% were observed on the average al income al project, with statistically significant improvement in on the 5 and 10 to 92% on the average of saturation of O₂ to air environment. The 88% of the patients they had presence of eosinophils in nasal mucus and 74% of them also they presented positiveness in the IgE. With regard to the demonstrations in high respiratory ways the clinical improvement was evident being established al five. Day absence of nasal flow improving in significant form the free step of the air by the high respiratory ways, with absence of sibilants and cough. Conclusions: This study concludes that the employment of the combination ambroxol-salbutamol-loratadina, is an excellent therapeutic alternative in children with episodes of bronchial hyper-reactivity induced by allergens.

REFERENCES

1. Global Strategy for Asthma. Management and prevention. National Institutes of Health. Revised 2002.

2. Sakula A. Drugs Used in Asthma. The Pharmacological Basis of therapeutics. 9th Ed. New York 1999: 659-682.

3. Antihistamínicos en el asma infantil. Dr. José Miguel escamilla. Pediatra Neumólogo Universidad de Cartagena.